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The promyelocytic leukemia (PML) protein is the main component of PML nuclear bod-
ies, which have many functions in a wide range of cell types. Until recently, PML was
not known to have a function in the nervous system or even be expressed in the brain.
However, recent reports have changed that view. PML is found in neurons and functions
in many aspects of the nervous system, including brain development, circadian rhythms,
plasticity, and the response to proteins that cause neurodegenerative disorders. While the
investigation of PML in the brain is still in its infancy, it promises to be a fascinating subject
that will contribute to our understanding of the brain. Here we summarize what is known
about PML expression and function in the brain and highlight both discrepancies in the
field and areas that are particularly important to future research.
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INTRODUCTION
Promyelocytic leukemia originally identified from its role in acute
PML. In this form of cancer, a chromosomal translocation results
in a fusion protein containing PML and the retinoic acid receptor.
The role of PML in cancer and several other cell types, partic-
ularly those involved in the immune response, has been exten-
sively investigated (1–3). PML and the nuclear bodies they form
carry out their functions through a variety of mechanisms from
transcriptional regulation to protein degradation.
While the initial characterizations of PML uncovered no signif-
icant expression in the nervous system, more recent publications
show it is expressed in dividing neural precursors and mature
neurons. In these cells, it appears to regulate transcription, but the
mechanisms are not yet understood.
In this review, we will describe the context in which PML is
expressed in the nervous system and what is known about how
this expression is regulated. We will also describe its functions in
the nervous system and discuss the numerous areas that require
more research for a complete understand of PML in the brain.
PML EXPRESSION AND REGULATION IN THE BRAIN
Initial publications sought to characterize PML in neurons (4, 5) or
neuron-like cells (6) and found little or no PML expression. How-
ever, upon closer examination, it is difficult to draw conclusions
about PML in the adult brain from these findings.
The evidence that PML nuclear bodies are not found in mature
neurons is not compelling. For example, one paper often cited in
support of this position did not directly examine PML expression.
The investigators characterized the staining pattern of an antibody
resulting from mice injected with rat lymphocytes (5). While the
antibody colocalized with PML nuclear bodies, it was not clear
whether it recognized PML or one of the many proteins often
found in the PML nuclear body that might not be expressed in
neurons. Another commonly cited paper focused on NT2 cells, a
neuronally committed human teratocarcinoma cell line (6). NT2
cells had low levels of PML expression, but when they were induced
to differentiate into neuron-like cells, they expressed high levels of
PML. It is difficult to draw conclusions about neurons from a car-
cinoma cell line, but the data presented in this paper do not suggest
a lack of PML in neurons.
Regad et al. performed one of the first thorough examinations
of PML in the brain, focusing on the developing neocortex (4).
They found that PML is expressed in the ventricular zone at embry-
onic day 15. They also found expression in the ventricular zone but
not in the cortical plate at postnatal days 0 and 7. However, a small
number of cells expressed PML in the hippocampus in postnatal
brains. The data characterize PML expression in the developing
brain and also convincingly demonstrate that PML had a func-
tional role in brain development (discussed in more detail below).
Yet, these data did not rule out the possibility that PML is also
expressed in mature neurons later in development or adulthood.
In fact, the presence of PML in a subset of postnatal hippocampal
cells suggests that it is expressed in fully differentiated neurons
under specific conditions. This expression pattern suggests that
PML is a highly regulated protein in the brain that is expressed in
response to specific stimuli.
Other studies support the idea that PML is expressed in the
brain in a highly regulated manner. PML RNA is present in the
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suprachiasmatic nucleus (SCN) of adult mice, which is involved
in regulating circadian rhythms. Furthermore, the pattern of PML
expression was highly regulated: PML protein levels peaked at spe-
cific times during the circadian cycle (7). In addition, PML was
expressed in the hippocampus, cortex, cerebellum, and brain stem
in adult mice (8).
One confounding issue with these studies is that brain tis-
sue contains glial cells. Thus, these findings are not conclusive
proof that PML is expressed in mature neurons. However, studies
in neuronal culture systems provide additional support for PML
expression in neurons. PML is expressed in neurons at low levels
in a neuronal culture system that lacks glia. Upon neuronal stimu-
lation, PML protein expression is significantly upregulated, as seen
by western blot and live-cell imaging (9).
Other studies examined PML expression in the context of neu-
rodegenerative disorders and stroke models. Using western blots
and immunohistochemical analysis, Hayashi et al. found PML
was upregulated in neurons in response to transient middle cere-
bral artery occlusion (10). PML is expressed in neurons in the
presence of mutant polyglutamine proteins, such as ataxin (11,
12), and colocalizes with intranuclear inclusions in diseases, such
as frontotemporal dementia (13). In some cases, PML is upreg-
ulated or PML nuclear bodies are rearranged or disrupted in
response to these proteins and in the neurodegenerative diseases
caused by these proteins (11, 12, 14–16). Interestingly, the cytokine
interferon beta, which induces PML nuclear body formation in
immune cells, also appears to increase PML expression in neu-
rons in Purkinje cells in a culture model of spinocerebellar ataxia
(11, 17).
These data present a multifaceted picture of PML expression
in the brain. PML is clearly expressed in early development and in
aging neurons in the context of neurodegenerative disorders. Its
presence in mature, healthy neurons appears to be more complex.
A recent review hypothesized that, after development is com-
plete, the adult brain may reacquire PML expression (18). The
evidence supports this idea and indicates that PML is expressed
in mature neurons under certain conditions, including in the
SCN during stages of the circadian cycle, and in response to
external stimuli, such as neuronal activity (Figure 1). These find-
ings also suggest that it has an important functional role the
brain.
PML FUNCTION IN THE BRAIN
Promyelocytic leukemia has several distinct functions in the ner-
vous system, including neuronal development, circadian rhythm
regulation, synaptic plasticity, and the neuronal response to toxic
proteins that cause neurodegenerative disorders. PML is most
commonly studied in the context of dividing cells, and not sur-
prisingly, one of the first indications of the importance of PML in
the brain came from studies of the dividing neural progenitor cells
(NPCs) during brain development (4). Regad et al. found that
NPCs from PML knockout mice (PML−/− mice) have reduced
differentiation into neurons that results in a decrease in thickness
of the cortex wall. In NPCs, PML regulates the distribution of
the retinoblastoma protein and the protein phosphatase 1α. This
triggers retinoblastoma protein dephosphorylation, which regu-
lates the transition between radial glial cells and basal progenitor
cells.
FIGURE 1 | Model of PML function in neurons. (A) In NPCs, PML
regulates subcellular localization of protein phosphatase 1α (PP1α) and
retinoblastoma protein (pRB), which results in dephosphorylation of pRB
and controls neuronal differentiation. (B) In mature neurons, PML is
involved in synaptic plasticity and circadian rhythms. In response to
increased activity, Arc mediates an increase in PML nuclear bodies which
results in transcription regulation. In the SCN, SIRT1 regulations acetylation
of PML which affects PER2 binding and transcription of genes that control
circadian rhythms. (C) In aging neurons, toxic polyglutamine proteins
accumulate at PML nuclear bodies. The result of this accumulation is not
known in most cases but can lead to the clearance proteins in specific
neurodegenerative disorders.
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In addition to its role in brain development, PML also has a
role in mature neurons. As described above, PML is expressed in
the SCN, which regulates the circadian clock (7). In the SCN, it
interacts with the clock regulator PER2 and enhances transcription
of circadian clock genes. SIRT1 deacetylates PML at K487, which
regulates the interaction of PML and PER2. In PML−/− mice,
the expression of Per2 and other clock regulators is disrupted,
and the circadian period has reduced precision and stability. The
developmental deficits in PML−/− mice can have confounding
effects for studies of the adult brain in these mice. However, in
this case, evidence that does not rely on the PML knockout mice
also supports a functional role for PML in the adult brain in
regulating circadian rhythms. For example, the authors demon-
strate that SIRT1 deacetylates PML by SIRT1 knockdown and
show that PML regulates transcription of clock genes through
PER2 by PML overexpression in combination with PER2 knockout
mice.
Increasing evidence also supports a role for PML in regulating
synaptic plasticity in the brain. Bloomer et al. found that PML
interacts with the protein Arc (19). Arc is crucial for learning and
memory and is involved in multiple forms of synaptic plastic-
ity, the molecular mechanisms that underlie memory formation
(20, 21). We found that PML is regulated by neuronal activity
and required for the neuronal response to increased activity. The
protein Arc mediates the activity-induced increase in PML, and
PML is required for Arc’s effects on transcription of genes that
control synaptic strength (9). Through this mechanism, PML is
involved in homeostatic plasticity, which allows neurons to main-
tain the same firing rate in the presence of persistent changes
in activity and is crucial to their ability to store information.
In addition to this new evidence, a further suggestion of PML’s
involvement in plasticity comes from its known interacting part-
ner death-associated protein 6 (DAXX). DAXX acts as a chaperone
for the histone H3.3 variant and promotes H3.3 loading at regula-
tory regions of activity-dependent genes in response to neuronal
stimulation (22). The role of PML in this process is not yet known,
but could be another aspect of PML’s involvement in regulat-
ing the neuronal response to activity in the context of synaptic
plasticity.
If PML is involved in regulating the cellular plasticity mecha-
nism that mediates memory formation, PML−/− mice should have
deficits in learning and memory. In fact, PML−/− mice have several
phenotypes relevant to cognitive function (8). They have deficits
in conditioned fear learning and spatial memory measured by fear
conditioning and Morris water maze tests. In addition, they display
deficient long-term depression and, depending on the induction
protocol used, have an enhanced response to long-term potenti-
ation induction. However, it is not yet known if these deficits are
due to PML function in mature neurons or to developmental prob-
lems in PML−/− mouse brains. In addition, PML−/− mice show
decreased anxiety-related responses, which contribute to some of
the learning phenotypes.
In addition to these functions in mediating the neuronal
response to activity in healthy neurons, PML is also involved in the
response to toxic proteins that cause neurodegenerative disorders.
As described above, many such polyglutamine proteins colocalize
with PML or result in disruption or rearrangement of PML nuclear
bodies. However, this alone is not evidence of PML’s involvement
in these disorders. In most cases, it is not clear whether the accu-
mulation of proteins at PML nuclear bodies and rearrangement
of the structures cause the neuronal dysfunction, are a beneficial
coping response to the toxic protein, or are inconsequential to the
disease. For example, PML nuclear bodies contain protein degra-
dation machinery, and polyglutamine proteins may be targeted
for degradation as the cell tries to clear the toxic protein. Colo-
calization of PML and polyglutamine proteins may result as the
highly expressed proteins accumulation at sights of protein degra-
dation machinery, regardless of whether PML is effective in the
clearance aggregated proteins. However, in at least one case, PML
induction appears to mitigate neurodegeneration. In a cell model
of spinocerebellar ataxia-7, PML degrades mutant ataxin-7 (17).
In a mouse model of the disease, increasing PML nuclear body
formation with interferon beta resulted in increased clearance of
ataxin-7 and improved the animals performance on behavioral
tests (11).
In summary, PML expression in the brain is regulated by var-
ious enzymes and external signals, and PML has several impor-
tant functions in neurons and neuronal precursors. PML car-
ries out its functions by regulating subcellular distribution of
critical proteins in neuronal development, transcriptional reg-
ulation in circadian rhythms and synaptic plasticity, and pro-
tein clearance of toxic proteins (Figure 1). However, clearly
much about PML regulation and function in the brain is still
unknown.
FUTURE DIRECTIONS
While PML was initially studied in the context of cancer, it
clearly has important functions in other cell types such as
neurons. A better understanding of the role of PML in non-
dividing cell types such as neurons will allow for a more com-
plete picture of the wide range of PML’s functions and may
even help provide insight into the functions that are disrupted
when PML expression is misregulated in certain cancers. It will
also be important to understand PML function in the brain
if new approaches to cancer treatment focus on activation of
PML (23).
Multiple publications demonstrated that PML has important
functions in the brain but clearly much is left to be discovered
about PML nuclear bodies in neurons. Probably the least under-
stood area is the mechanisms through which PML carries out
its proposed functions. PML nuclear bodies regulate a variety of
nuclear functions involved in everything from transcriptional reg-
ulation and protein degradation to RNA processing. This makes
it difficult to assign a specific mechanism through which PML
nuclear bodies carry out their functions. In most of the pub-
lications described in this review, it is not yet understood how
PML is actually mediating the neuronal processes it regulates. In
several cases (such as in circadian rhythms and plasticity), PML
appears to regulate transcription. But how it does is not clear.
We hypothesized that PML regulates transcription through CREB
binding protein (CBP), one of its major binding partners. CBP
and CREB are critical proteins in neuronal function, so a role for
PML in regulating or degrading CBP would have important con-
sequences for neurons (24, 25). A new area for investigation will
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involve determining how PML is able to affect transcription in
neurons.
Second, it will ultimately be necessary to determine if the
deficits in PML−/− mice are due to the developmental problems
in the brains of these mice or are because of PML’s actions in
mature neurons. Studies of learning deficits in the knockout mice
are intriguing but cannot definitively be attributed to a function
of PML in development or in regulating plasticity in mature neu-
rons. A conditional PML knockout or knockdown model that only
disrupts PML expression in mature neurons will be beneficial in
answering these questions.
Finally, the role of PML in disease is unclear. While PML appears
to colocalize with many polyglutamine proteins that cause neu-
ronal dysfunction, in most cases it is not clear what the effects
of this are. PML has a large number of protein binding partners,
and the nuclear bodies contain protein degradation machinery.
Because of this, many proteins that are expressed in the nucleus
colocalize with some component of these nuclear structures or
are targeted there for degradation. In the case of highly expressed
polyglutamine proteins, many of which aggregate and overload
protein degradation machinery, it is not surprising that such aggre-
gates might accumulate at these structures after being targeted
for degradation. While the disruption of the PML body in many
of these disorders is intriguing, it is too soon to conclude that
PML plays an important role in these diseases. Future studies
will need to make use of PML−/− mice or PML knockdown as
well as PML induction in order to conclude that PML is either
beneficial to the disorder or involved in the resulting neuronal
dysfunction.
CONCLUSION
From the data described here, we conclude that PML is expressed
in at least some regions of the brain through the lifetime of a neu-
ron, from development to death. PML expression is also clearly
regulated in neurons both by external signals and intracellular
proteins. As in other cell types, PML appears to have multiple
functions in neurons and can regulate transcription in the context
of plasticity and circadian rhythms and protein degradation in
response to toxic proteins. However, much is still unknown about
PML in the brain, and we expect this will be an area of fascinating
new research in the future.
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